October 22, 2019 – PRMS
Subsites are currently not receiving activation emails for amendments. A solution for this is in development. For now, please check OncPro to see if the submission is active.
Do it right. Do it better.
Beating cancer isn't easy. Neither is running a clinical trial. We need to do it right and do it better.
At the Dana-Farber/Harvard Cancer Center, our investigators are renowned for cutting-edge and ground-breaking science. The ODQ brings that same innovative spirit to clinical research quality and operations.
Let's move research forward. The fight against cancer is too important not to.
ODQ News & Updates
-
-
October 21, 2019 – PRMS
All communication emails relating to a specific trial will be sent to the staff listed in iRIS under Study Contact. At time of new submission, the Overall PI will default to be listed as a study contact. If the PI has...
-
October 20, 2019 – PRMS
Sub-site study status is not automatically updated when the lead site submits a status change amendment in iRIS. Sub-site status may also be an issue for migrated studies where an NPA or add site submission was submitted...